8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Apr 25, 2014)

Filed April 25, 2014For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed a Form 8-K on April 25, 2014, to report its financial results for the first quarter of 2014. The primary purpose of this filing was to furnish the press release announcing these results, which is attached as Exhibit 99.1. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification to investors that AbbVie has publicly disclosed its Q1 2014 performance. Investors should refer to the furnished press release (Exhibit 99.1) for specific details regarding AbbVie's operational and financial performance during the first quarter. This typically includes revenue figures, earnings per share (EPS), and commentary on key products and business segments. The filing highlights the company's commitment to timely disclosure of material financial information.

Key Highlights

  • 1AbbVie Inc. filed an 8-K on April 25, 2014, to report its Q1 2014 financial results.
  • 2The filing primarily furnished a press release detailing the Q1 2014 financial performance.
  • 3Investors are directed to the press release (Exhibit 99.1) for specific financial data.
  • 4The report confirms the company's adherence to SEC reporting requirements for financial results.
  • 5William J. Chase, Executive Vice President and Chief Financial Officer, signed the report.
  • 6The filing falls under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report AbbVie's financial results for the first quarter of 2014 by furnishing the press release that contains these results.

The detailed financial results are available in the press release dated April 25, 2014, which is included as Exhibit 99.1 to this 8-K filing.

No, the 8-K document itself does not contain the specific financial numbers. It only references and attaches the press release where those details are disclosed.

The report was signed by William J. Chase, Executive Vice President and Chief Financial Officer of AbbVie Inc.